Can Prostate-Specific Antigen and Prostate-Specific Antigen Velocity Be Used for Prostate Cancer Screening in Men Older Than 70 Years?

Urology

Volumn 71, Issue 6, 2008, Pages 1020-1023

  Mouraviev, Vladimir ^a   Broadwater, Gloria ^a   Sun, Leon ^a   Mayes, Janice M ^a   Moul, Judd W ^a   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 44649114100     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.016     Document Type: Article

References (16)

1. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293-306
2. Efstathiou J.A., Chen M.H., Catalona W.J., et al. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 68 (2006) 342-347
3. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56 (2000) 255-260
4. Smith R.A., von Eschenbach A.C., Wender R., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 51 (2001) 38-75
5. Hoffman R.M. Viewpoint: limiting prostate cancer screening. Ann Intern Med 144 (2006) 438-440
6. Centers for Disease Control and Prevention. National Center for Health Statistics. http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/lftbls.htm accessed on March 27, 2007
7. Catalona W.J., Loeb S., and Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 144 (2006) 441-443
8. Ford M.E., Havstad S.L., Demers R., et al. Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. Cancer Epidemiol Biomarkers Prev 14 (2005) 190-194
9. Scales Jr. C.D., Curtis L.H., Norris R.D., et al. Prostate specific antigen testing in men older than 75 years in the United States. J Urol 176 (2006) 511-514
10. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
11. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
12. Moul J.W., Sun L., Hotaling J.M., et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 177 (2007) 499-503 discussion 503-504
13. Nadler R.B., Loeb S., Roehl K.A., et al. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 174 (2005) 2154-2157 discussion 2157
14. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
15. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
16. Moul J.W., Sesterhenn I.A., Connelly R.R., et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274 (1995) 1277-1281